Aetram Research India - Nifty Pharma - Weekly Sector Outlook
Aetram Research India - Nifty Pharma - Weekly Sector Outlook
NIFTY PHARMA trades range bound near 22,800; mild bullish bias above 22,550, weakness resumes only below 22,300 - 03.01.2026
Current Market Price: 22790.90
Market Prediction
- NIFTY PHARMA is consolidating within a broader upward structure, holding above key moving averages. Momentum remains moderate, indicating balance between buyers and sellers. Sustained trade above resistance can trigger a fresh upside attempt, while failure to defend supports may extend sideways to corrective movement.
Upcoming Events (Catalysts)
- USFDA inspection outcomes
- Global generic drug pricing trends
- Rupee movement against dollar
Major Support and Resistance
- Support: 22580 / 22350 / 22100
- Resistance: 22950 / 23200 / 23500
Volume Analysis
- Volume activity remains average with no major expansion, reflecting lack of aggressive participation. Breakouts or breakdowns without volume confirmation may lack follow-through, keeping price action confined within a defined range for now.
Final Takeaway
- NIFTY PHARMA remains in consolidation with a slightly positive bias. The structure favors selective buying near supports and cautious participation on breakouts, while sustained weakness below key levels would negate the current stabilization phase.
Next Week Prediction
- NIFTY PHARMA is likely to trade between 22100 and 23500. A sustained move above 22950 may lead to further upside, while a break below 22350 could shift the bias toward deeper consolidation or corrective decline.
Breakout Strategy (Bullish)
- Entry: Buy above 22950 / Stoploss: 22580
- Targets: 23200 / 23500 / 23850
Breakdown Strategy (Bearish)
- Entry: Sell below 22350 / Stoploss: 22750
- Targets: 22100 / 21850 / 21600
Disclaimer: This analysis is for educational purposes only and does not constitute investment advice. Market conditions can change without notice. Please consult a qualified financial advisor before making any trading or investment decisions.
